Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rydén, L.
Right arrow Articles by Gadler, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rydén, L.
Right arrow Articles by Gadler, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Pharmacological therapy for hypertrophic cardiomyopathy: what is the evidence for success?

L. Rydén* and F. Gadler

Department of Cardiology, Karolinska Hospital, Stockholm, Sweden

* Correspondence: Lars Rydén, MD, Professor of Cardiology, Department of Cardiology, Karolinska Hospital, S-171 76 Stockholm, Sweden.

Abstract

The available experience from studies of pharmacological treatment of patients with hypertrophic cardiomyopathy was mainly gained in selected patient samples, with severe symptoms or a complicated clinical setting. Moreover, most reports on drug efficacy are based on either acute mechanistic studies or non-controlled patient cohorts, which are usually rather restricted in numbers and followed for limited periods of time. Bearing in mind the symptomatic presentation of hypertrophic cardiomyopathy, which is sometimes highly variable and influenced to a degree by sympathetic arousal, it is understandable that a considerable placebo effect may occur when initiating any type of treatment. Considering the pathophysiology that underlies symptoms of hypertrophic cardiomyopathy, it is not surprising that the pharmacological agents that are most advocated are beta-blockers and calcium channel blockers - drugs that impact on several of the factors that are responsible for the symptoms. Other compounds that may be used include antiarrhythmic drugs, of which disopyramide - combining antiarrhythmic with negative inotropic properties - has attracted particular interest.

Key Words: Treatment • pharmacological • cardiomyopathy • hypertrophic • symptoms • evidence

References

  1. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20:1–8
  2. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775–785[Free Full Text]
  3. Spirito P, Chiarella F, Carratino L, et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med. 1989;320:749–755[Abstract]
  4. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol. 1993;72:970–972[CrossRef][Web of Science][Medline]
  5. Linde C, Gadler F, Kappenberger L, Rydén L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. Am J Cardiol. 1999;83:903–907[CrossRef][Web of Science][Medline]
  6. gwathemey JK, Warren SE, Briggs GM, et al. Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. J Clin Invest. 1991;87:1023–1031
  7. Sherrid MV, Gunsburg D, Sharma A. Medical treatment of hypertrophic cardiomyopathy. Curr Cardiol Rep. 2000;2:148–153[Medline]
  8. Webb-Peploe MM. Hypertrophic cardiomyopathy. Role of betablockers in therapy. Zipes DP, Rowlands DJ. Progress in Cardiology. London: Lea and Febiger; 1989. p. 167–181
  9. Gilligan DM, Chan WL, Joshi J, et al. A double-blind, placebocontrolled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;21:1672–1679[Abstract]
  10. Swanton RH, Brooksby IA, Jenkins BS, Webb-Peploe MM. Hemodynamic studies of beta blockade in hypertrophic obstructive cardiomyopathy. Eur J Cardiol. 1977;5:327–331[Web of Science][Medline]
  11. Kaltenbach M, Hopf R, Kober G, et al. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J. 1979;42:35–42[Abstract/Free Full Text]
  12. Hess OM, Seiler C, Krayenbuehl HP. Hypertrophic cardiomyopathy. Role of calcium antagonists in therapy. Zipes DP, Rowlands DJ. Progress in Cardiology. London: Lea and Febiger; 1989. p. 157–166
  13. Gistri R, Cecchi F, Choudhury L, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol. 1994;74:363–368[CrossRef][Web of Science][Medline]
  14. Tendera M, Schneeweiss A, Bartoszewski A, et al. The acute response of left ventricular filling dynamics to intravenous verapamil predicts the changes in exercise tolerance after oral verapamil therapy in patients with hypertrophic cardiomyopathy. Eur Heart J. 1993;14:410–415[Abstract/Free Full Text]
  15. Seiler C, Hess OM, Schoenbeck M, et al. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study. J Am Coll Cardiol. 1991;17:634–642[Abstract]
  16. Toshima H, Koga Y, Nagata H, et al. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study. Jpn Heart J. 1986;27:701–715[Medline]
  17. Pollick C. Disopyramide in hypertrophic cardiomyopathy. Noninvasive assessment after oral administration. Am J Cardiol. 1988;62:1252–1255[CrossRef][Web of Science][Medline]
  18. Hartmann A, Kühn J, Hopf R, et al. Effect of propranolol and disopyramide on left ventricular function at rest and during exercise in hypertrophic cardiomyopathy. Cardiology. 1992;80:81–88[Web of Science][Medline]
  19. Niki K, Sugawara M, Asano R, et al. Disopyramide improves the balance between myocardial oxygen-supply and demand in patients with hypertrophic obstructive cardiomyopathy. Heart Vessels. 1997;12:111–118[Web of Science][Medline]
  20. Kober G, Hopf R, Biamino G, et al. Long-term treatment of hypertrophic cardiomyopathy with verapamil or propranolol in matched pairs of patients: results of a multicenter study. Z Kardiol. 1987;76(suppl 3):113–118
  21. Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. Effects on exercise capacity and symptomatic status. Circulation. 1979;60:1208–1213[Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rydén, L.
Right arrow Articles by Gadler, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rydén, L.
Right arrow Articles by Gadler, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?